CompanyUnited StatesUpdated Apr 4, 2026
2048 Ventures

2048 Ventures

2048 Ventures: Investor, Venture Capital • focus on Venture Capital • active in North America, United States • offices in United States • AUM $82M.

Never miss breaking news

Get instant notifications when new news matching "2048 Ventures" are published.

Company Profile

2048 Ventures is a thesis-driven early-stage venture capital firm based in New York City and Boston, dedicated to backing visionary founders who are building transformative technologies. The firm focuses on leading Pre-Seed and Seed rounds, typically writing checks between $500K and $3M. They are particularly interested in next-generation platforms with strong data moats, including Systems of Record, infrastructure, and API companies.

The firm's core investment areas are Vertical AI, Deep Tech, Health, and Bio. They emphasize a founder-friendly approach, aiming for quick conviction and commitment to lead rounds within 10-15 business days, with a special Pre-Seed Fast Track for funding within 10 business days for Pre-Seed rounds up to $1.5M. 2048 Ventures prides itself on an NPS score of 100 from its founders, highlighting its commitment to being a helpful and supportive partner from day zero.

Founded in 2018 by Alex Iskold and Paul Sethi, 2048 Ventures leverages a team of experienced founders, operators, engineers, and scientists. Alex Iskold is a 5x founder, software engineer, and investor, who previously served as Managing Director of Techstars NYC. Partners Zann Ali and Julie Wolf, PhD, bring diverse expertise in finance, strategy, and scientific research, with Julie leading the biotech and healthcare verticals. The team also includes Principal Daniella Cohen, Senior Associate Sandra Pérez Baos, PhD, and Associate Edward Jin, all contributing to the firm's deep industry knowledge and founder support.

Recent investments include Pocket, an AI front-office for rehab therapy clinics, and Broome AI, an agentic AI platform for commercial real estate investment teams. The firm also recently announced an oversubscribed $82,048,000 Fund III in January 2026, further solidifying its capacity to invest in its core focus areas within NYC and Boston. Their investment theses cover areas like Reproductive Longevity and Drug Delivery, showcasing a forward-thinking approach to healthcare and biotech innovation.

News & Signals (0)

No linked news activity found for this company.

Investor Listings

Similar Companies

Ranked by shared taxonomies: sector, subsector, geography, asset class and investor lists.

No similar companies found with overlapping taxonomy tags.